Vanguard Group Inc Windtree Therapeutics Inc Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.16 - $0.2 $46,036 - $57,546	-287,730 Reduced 63.1%	168,233 $28,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.7 $38,367 - $89,523	-127,890 Reduced 21.9%	455,963 $137,000
Q2 2022 Aug 12, 2022	BUY	$0.38 - $1.14 $12,380 - $37,140	32,579 Added 5.91%	583,853 $243,000
Q1 2022 May 13, 2022	SELL	$0.94 - $1.6 $112,054 - $190,731	-119,207 Reduced 17.78%	551,274 $629,000
Q3 2021 Nov 12, 2021	BUY	$1.66 - $2.27 $73,743 - $100,842	44,424 Added 7.1%	670,481 $1.38 Million

Q2 2021 Aug 13, 2021	BUY	$1.68 - $2.79 $1.05 Million - $1.75 Million	626,057 New	626,057 $1.43 Million

4.09K

Ticker WINT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,627,900
Market Cap $97.4M
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.